GleamWall
中文EN

OBX Obsidian Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 2130606 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets5.9%
Debt / equity0.00x
Current ratio12.29x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q32025-09-302025Q22025-06-302025Q12025-03-31
Income statement
Revenue$0——$0——
R&D expense$27.55M——$25.05M——
SG&A expense$10.32M——$4.59M——
Operating income-$52.91M——-$29.63M——
Pretax income-$50.66M——-$28.47M——
Income tax$0——$0——
Net income-$50.66M-$25.86M-$19.63M-$28.47M-$26.90M-$24.99M
EPS (basic)-1.23——-14.77——
EPS (diluted)-1.23——-14.77——
Weighted avg. shares (diluted)41.03M——1.93M——
Balance sheet
Cash & equivalents$66.51M$0—$37.36M——
Short-term investments$148.40M—————
Current assets$224.54M$0————
PP&E, net$961,000—————
Total assets$340.74M$0————
Current liabilities$18.26M$0————
Total liabilities$20.16M$299.71M————
Shareholders' equity$320.58M-$299.71M-$276.20M-$247.63M-$221.44M-$197.30M
Shares outstanding61.77M1,000————
Cash flow statement
Operating cash flow—$0————
Investing cash flow—$0————
Financing cash flow—$0————
Stock-based compensation$2.26M——$2.23M——

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.